+

WO2017066355A1 - Stents pourvus d'éléments saillants d'administration de médicament et systèmes et procédés associés - Google Patents

Stents pourvus d'éléments saillants d'administration de médicament et systèmes et procédés associés Download PDF

Info

Publication number
WO2017066355A1
WO2017066355A1 PCT/US2016/056688 US2016056688W WO2017066355A1 WO 2017066355 A1 WO2017066355 A1 WO 2017066355A1 US 2016056688 W US2016056688 W US 2016056688W WO 2017066355 A1 WO2017066355 A1 WO 2017066355A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
delivery
expandable element
delivery features
body lumen
Prior art date
Application number
PCT/US2016/056688
Other languages
English (en)
Inventor
John Fulkerson
Isa Rizk
Jihad A. MUSTAPHA
Teodoro S. Jimenez, Jr.
Original Assignee
Reflow Medical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reflow Medical, Inc. filed Critical Reflow Medical, Inc.
Priority to CA3001249A priority Critical patent/CA3001249C/fr
Priority to EP16856132.2A priority patent/EP3362006B1/fr
Priority to AU2016339033A priority patent/AU2016339033B2/en
Priority to CN202211482262.7A priority patent/CN115778654A/zh
Priority to JP2018538539A priority patent/JP7145757B2/ja
Priority to CN201680072455.1A priority patent/CN108366866A/zh
Priority to ES16856132T priority patent/ES2906444T3/es
Publication of WO2017066355A1 publication Critical patent/WO2017066355A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/848—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/848—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having means for fixation to the vessel wall, e.g. barbs
    • A61F2002/8483—Barbs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/95—Instruments specially adapted for placement or removal of stents or stent-grafts
    • A61F2002/9528—Instruments specially adapted for placement or removal of stents or stent-grafts for retrieval of stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00—Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0008—Fixation appliances for connecting prostheses to the body
    • A61F2220/0016—Fixation appliances for connecting prostheses to the body with sharp anchoring protrusions, e.g. barbs, pins, spikes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0023—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in porosity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
    • A61F2250/0098—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers radio-opaque, e.g. radio-opaque markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/44—Radioisotopes, radionuclides

Definitions

  • the present technology relates generally to expandable elements, such as stents or scaffolds having spikes, flails, or other protruding features for delivering drugs and/or penetrating target tissue within a human patient.
  • a drug-eluting stent can be positioned at the location of a stenosis (arterial narrowing) caused by arteriosclerosis.
  • DESs generally include a drug containing polymer coated over a metal stent or scaffold, or a bioresorbable stent or scaffold composed of a drug-containing polymer.
  • 85% or more of the stented vessel wall area may not be in contact with the stent struts. Accordingly, significant diseased portions of the vessel wall may not receive a desired dose or delivery of the drug will not be uniform throughout the treatment site. Additionally, portions of the DES may be in contact with blood, arterial plaque and/or with other fluid or materials within the vessel lumen that are not intended delivery sites for the drug. These issues can result in drug tissue concentrations that are lower than desired or less uniform than desired.
  • DEBs Drug-eluting balloons
  • non drug-eluting balloons provide an alternative to DESs, and can address some of the limitations discussed above. For example,
  • DEBs can also be delivered to a desired treatment location and expanded against a vessel wall to release a drug.
  • DEBs can include a coating of the drug over an entire surface area of the balloon that expands to be in uniform contact with the vessel wall. Accordingly, DEBs can provide a more uniform dose to the adjacent vessel tissue.
  • the drug when used in conjunction with angioplasty, can be delivered at the location and time of any vessel damage that occurs during the procedure. Even so, DEBs also have several limitations. For example, during the delivery of the drug (i.e., when the balloon is inflated), blood flow in the associated vessel is stopped or severely obstructed, and no other treatment devices can be passed through the vessel.
  • both DEBs and existing DESs fail to provide drug-delivery at all locations along an adj acent vessel wall. Specifically, uneven vessel walls, obstructions, contours, or other features can prevent the balloon surface or stent struts from reaching portions of the vessel wall. Moreover, existing DESs and DEBs do not provide for drug-delivery into the vessel wall (i.e., penetration of the vessel wall for drug-delivery within the tissue itself).
  • Figure 1 is a partially schematic side view of a portion of a drug delivery system in a delivery state (e.g., low-profile or collapsed configuration) within a body lumen and configured in accordance with an embodiment of the present technology.
  • a delivery state e.g., low-profile or collapsed configuration
  • Figure 2A is a side view of the portion of the drug delivery system of Figure 1 in a partially deployed state (e.g., expanded configuration) within the body lumen and configured in accordance with an embodiment of the present technology.
  • a partially deployed state e.g., expanded configuration
  • Figure 2B is a cross-sectional view of a portion of the drug delivery system of Figure 2A taken along line 2B-2B.
  • Figures 3A-3D are isometric views of portions of drug-eluting expandable structures having drug-delivery features configured in accordance with embodiments of the present technology.
  • Figure 4 is a cross-sectional view of a portion of a drug-eluting stent illustrating a drug-delivery feature configured in accordance with yet another embodiment of the present technology.
  • Figures 5A-5C are cross-sectional images of a portion of a blood vessel having a drug-eluting stent configured in accordance with an embodiment of the present technology expanded therein.
  • Figures 6A-60 are cross-sectional images of a portion of a blood vessel having a drug-eluting stent with square struts configured in accordance with another embodiment of the present technology expanded therein.
  • Figures 7A-7C are cross-sectional images of a portion of a blood vessel having a drug-eluting stent with round struts configured in accordance with yet another embodiment of the present technology expanded therein.
  • Figures 8A-8H are cross-sectional images of a portion of a blood vessel having a drug-eluting stent with pointed struts configured in accordance with still another embodiment of the present technology expanded therein.
  • Figures 9A-9K are cross-sectional images of a portion of a blood vessel having a drug-eluting stent with square struts configured in accordance with an embodiment of the present technology expanded near an atherosclerotic lesion therein.
  • expandable structures such as stents or scaffolds, having spikes, flails, or other protruding features for delivering drugs and/or penetrating target tissue within a human patient, and associated systems and methods.
  • the drug-delivery features can be integrally formed with expandable element, or may include separate features protruding from a strut or other member of the expandable element positioned to engage and/or penetrate a vessel wall.
  • several embodiments configured in accordance with the present technology include expandable structure with drug-delivery features for delivering drugs to deep intimal layers and/or medial layers of vessels.
  • the drug-delivery features can include spikes protruding from one or more struts or portions of the expandable structure.
  • the spikes can be configured to penetrate the vessel wall.
  • the drug-delivery features can include angular protrusion(s) extending from one or more struts. Such angular protrusions are expected to provide better contact with the vessel wall, moving past obstructions or other interfering material to more effectively deliver drugs to target tissue. Additionally, the angular protrusions can increase the surface area of the drug-delivery features in contact with the vessel wall, thereby providing for a more uniform delivery of the drug. Still other embodiments may eliminate particular components and/or procedures.
  • FIG. 1 is a partially schematic side view of a portion of a drug delivery system 100 (“the system 100") configured in accordance with an embodiment of the present technology.
  • the system 100 is in a delivery state (e.g., low-profile or collapsed configuration) within a body lumen 102 (e.g., blood vessel) of a human patient.
  • the system 100 includes, for example, a catheter 104 and a drug-eluting stent 106 carried in a delivery/collapsed state within a distal portion of the catheter 104.
  • inventions of the present technology can also include cages, meshes, balloons, membranes, tubular structures, circumferential bodies, expandable elements, expandable membranes, expandable structures, expandable tubular structures, and circumferentially expandable catheter tips with and without guidewire lumens.
  • the catheter 104 is configured for intravascular delivery through the body lumen 102 to position the drug-eluting stent 106 at a desired treatment location.
  • several embodiments can provide for detachment of a stent or other structure including the drug-delivery features.
  • a wire or attachment member can release the stent 106 via mechanical, thermal, electrical or other means.
  • the drug-eluting stent 106 can be operatively coupled to a circular or non-circular longitudinal member configured to release and/or recapture the drug- eluting stent 106 in the system 100.
  • the member can be coupled, either directly or indirectly, to a frame (1 1 1 of Figure 2A) of the drug-eluting stent.
  • the stent 106 or other structure can be designed for permanent placement within a patient.
  • Figure 2A is a partially schematic side view of the system 100 of Figure 1 in a partially deployed state (e.g., expanded configuration) within the body lumen 102.
  • the drug-eluting stent 106 has been advanced from a distal end of the catheter 104 and positioned adjacent a desired treatment site.
  • the stent 106 includes a plurality of struts 204 forming a radially expandable cylindrical frame 11 1 and members engaging with and extending between two or more rows of struts.
  • the struts 204 of the expanded drug-eluting stent 106 are in apposition with the walls of the body lumen 102.
  • the drug-eluting stent 106 further includes a plurality of drug-delivery features 206 carried by the struts 2204.
  • Several embodiments can be designed for application of a drug onto the stent or the drug-delivery features that are configured to receive a drug and release the drug once the stent is expanded at the desired treatment site.
  • Figure 2B is a cross-sectional view of a portion of the drug delivery system of Figure 2A taken along line 2B-2B.
  • the drug- eluting stent 106 includes a plurality of struts 204 having plurality of drug-delivery features 206 carried by the struts 204.
  • the drug-delivery features 206 are integrally formed portions of the struts 204, disposed across at least a portion of an outer dimension of the stent 106, and extending radially outward away from the stent 106 toward the target portion of the body lumen.
  • the drug-eluting stent 106 can be a self-expanding structure.
  • the drug-eluting stent 106 can be coupled to a balloon or other suitable techniques and/or structures known to those of skill in the art may be used to transform the drug-eluting stent 106 from the low-profile delivery state to the deploy ed/expanded state shown in Figure 2A.
  • the drug-eluting stent 106 can be operatively coupled to an actuation mechanism, such as a mechanical actuation mechanism, configured to position, expand, retract, re-position, and/or remove the drug-eluting stent 106.
  • the frame 11 1, struts 204, and/or drug-delivery features 112 can be composed of or formed from a variety materials including, e.g., nitinol, cobalt chromium, stainless steel, any of a variety of other metals or metal alloys, or a combination thereof.
  • the frame 11 1, struts 204, and/or drug-delivery features 112 may also be composed of or formed from bioresorbable biodegradable, nanoporous or non-bioresorbable, non-biodegradable, non- nanopourous materials including, e.g., one or more polymers, plastic materials, etc., or a combination thereof.
  • the frame 1 11 and the struts 204 can be formed from a bioresorbable material and the drug-delivery features 112 can be formed from a non- bioresorbable material, such as nitinol.
  • the drug-delivery features 1 12 can remain engaged with or penetrating a portion of the body lumen after the expanded frame 11 1 and struts 204 bio-resorb.
  • the body lumen where the drug-eluting stent 106 had been expanded is no longer partially occluded by the frame 1 11 and the struts 204 allowing for larger volumes of fluids, such as aqueous pharmaceutical compositions, to pass through the body lumen and contact the luminal wall.
  • the drug-delivery features 1 12 may also be formed of a bio-resorbable material and, once the drug-eluting stent 106 has bio-resorbed, the spaces in the body lumen wall vacated by the drug-delivery features 112 can be contacted by the fluids passing through the lumen. In this way, the drug-eluting stent 106 can increase a surface area of the lumen wall contacted by the fluid.
  • the material(s) for forming the frame 11 1, struts 204, and/or drug-delivery features 1 12 can be selected based on mechanical and/or thermal properties, such as strength, ductility, hardness, elasticity, flexibility, flexural modulus, flexural strength, plasticity, stiffness, emissivity, thermal conductivity, specific heat, thermal diffusivity, thermal expansion, any of a variety of other properties, or a combination thereof. If formed from a material having thermal properties, the material can be activated to deliver thermal treatment to the desired treatment site.
  • the frame 1 11 , struts 204, and/or drug-delivery features 1 12 can be formed from a tube or a wire, such as a solid wire, by laser cutting or other suitable techniques.
  • a portion of the wire can be removed by chemical etching or another suitable method to create an inner dimension of the drug- eluting stent 106.
  • drug-eluting stents 106 can be sized and shaped for placement within various body lumens, including blood vessels, while not rupturing the vessel.
  • body lumen e.g., vessel wall
  • drug-eluting stents 106 can be sized and shaped for placement within various body lumens, including blood vessels, while not rupturing the vessel.
  • several stents and other structures configured in accordance with the present technology can have radial strength that allows for features of the body lumen (e.g., vessel wall) to receive drugs without dissection or damage thereto.
  • Vessels in which the drug-eluting stents 106 may be sized and shaped for placement include arteries, such as coronary arteries, peripheral arteries, carotid arteries, circle of willis, anterior cerebral artery, middle cerebral artery, posterior cerebral artery, any of the lenticulostriate arteries, renal arteries, femoral arteries, veins, such as cerebral veins, saphenous veins, arteriovenous fistulas, or any other vessel that may contain a treatment site.
  • Drug-eluting stents 106 can have a variety of shapes, including a cube, a rectangular prism, a cylinder, a cone, a pyramid, or variations thereof.
  • the stent 106 and other structures having drug-delivery features configured in accordance with the present technology can include a variety of dimensions (in both the low- profile delivery state and expanded deployed state). These embodiments can provide for expansion that enables usage in a variety of situations covering a wide range of dimensions.
  • drug-eluting stents 106 can have a length of about 0.25mm, about 0.5mm, about 1mm, about 2mm, about 3mm, about 4mm, about 5mm, about 6mm, about 7mm, about 8mm, about 9mm, about 10mm, about 12mm, about 14mm, about 16mm, about 18mm, about 20mm, about 30mm, about 40mm, about 50mm, about 60mm, about 70mm, about 80mm, about 90mm, or about 100mm.
  • a drug-eluting stent 106 shaped into a cube, a rectangular prism, or a pyramid can have a width of about 0.25mm, about 0.5mm, about 1mm, about 2mm, about 3mm, about 4mm, about 5mm, about 6mm, about 7mm, about 8mm, about 9mm, about 10mm, about 12mm, about 14mm, about 16mm, about 18mm, about 20mm, about 25mm, or about 30mm.
  • a drug-eluting stent 106 shaped into a cylinder or a cone can have a diameter of about 0.25mm, about 0.5mm, about lmm, about 2mm, about 3mm, about 4mm, about 5mm, about 6mm, about 7mm, about 8mm, about 9mm, about 10mm, about 12mm, about 14mm, about 16mm, about 18mm, about 20mm, about 25mm, about 30mm, about 35mm, about 40mm, or about 50mm.
  • the width or the diameter of the drug-eluting stent 106 can decrementally decrease along a length of the stent.
  • the drug-eluting stent 106 can be sized and shaped to prepare the body lumen for certain procedures, such as a drug-eluting stent placement procedure.
  • Profiles of the drug-eluting stents or other structures can be sized such that the drug-eluting stents or other structures are compatible with a wide range of catheter sizes.
  • Embodiments in accordance with the present technology can include drug-eluting stents or other structures designed to receive a guidewire, such as guidewires having a diameter of 0.010, 0.014, 0.018, 0.035, or 0.038 inch.
  • the stent or scaffold structure can be sized and designed for delivery via a micro-catheter that it is pushed through.
  • stents or structures configured in accordance with the present technology can be incorporated into a delivery system, including modular or single unit delivery systems.
  • the drug-eluting stent 106 can include a marking for visualization of the stent 106 within the body lumen, such as one or more radiopaque markers.
  • the radiopaque markers can be formed from Clearfil Photo Core PLT®, tantalum, titanium, tungsten, barium sulfate, and zirconium oxide, or another suitable radiopaque marking.
  • the markings can be formed on a proximal portion of the drug-eluting stent 106, a distal portion, an intermediate portion, or a combination thereof.
  • the markings can be a band, a coil, a clip, filled into one or more portions of a tube in the stent, plated onto one or more portions of the stent, or a combination thereof. Regardless of the type of marking, the marking can be coined, swaged, wrapped, or encased along, or onto any portion of the stent.
  • Stents and other structures configured in accordance with the present technology can be flexible enough to track through various anatomical features, including those having a curvature.
  • the flexible properties of the stent and other structures can be provided by the material from they are formed.
  • flexible properties can also be provided by fracturing one or more of the members engaging with and extending between two or more rows of struts.
  • the drug-eluting stent or other structure can be readily deployed and expanded, and retracted and contracted.
  • the drug-eluting stent or other structure can also be readily repositioned within a vessel or other lumen.
  • the drug-eluting stent 106 includes drug- delivery features 206 carried by the strut 204.
  • the drug-delivery features 206 may also be carried by more than one strut 204, the frame 111, or a combination thereof.
  • the drug- delivery features 206 may be integrally formed with the struts 204, for example by bending or twisting a portion of one or more struts and/or the frame 111 away from a longitudinal axis of the stent 106 or, alternatively, the drug-delivery features 206 may be separate, discrete components that are attached to desired locations along the struts 204 and/or the frame 111.
  • the drug-delivery features 206 are integrally formed with the struts 204.
  • the drug-delivery features 206 may have a variety of different shapes, sizes, and configurations.
  • the drug-delivery features disclosed herein enhances engagement with and/or penetration of the lumen wall, provides enhanced drug-delivery, and allows for better treatment at the desired location.
  • the drug-delivery features 206 can be protruding members.
  • a drug-eluting compound is coated onto at least a portion of the drug-delivery features.
  • the drug-eluting compound can be a synthetic or biological polymer coated into a variety of different patterns and thicknesses suitable for delivering the drug contained therein.
  • the drug-delivery features themselves may be composed of drug-eluting materials.
  • the drug carried by the drug-eluting compound and/or the drug-delivery features in accordance with the present technology can be any drug suitable for treating the treatment site in which the drug-eluting stent will be placed and may or may not include an excipient.
  • the drug can be an anti-proliferative, an anti-neoplastic, a migration inhibitor, an enhanced healing factor, an immunosuppressive, an anti-thrombotic, a blood thinner, or a radioactive compound.
  • anti-neoplastics include, but are not limited to, siroliums, tacrolimus, everolimus, lefiunomide, M- prednisolone, dexamethasone, cyclosporine, mycophenolic acid, mizoribine, interferon, and tranilast.
  • anti-proliferatives include, but are not limited to, taxol/paclitaxel, actinomycin, methotrexate, angiopeptin, vincristine, mitmycine, statins, c-myc antisense, Abbot ABT-578, RestinASE, 2-chloro-deoxyadenosine, and PCNA ribozyme.
  • migration inhibitors include batimistat, prolyl hydrosylase, halofunginone, c-preteinase inhibitors, and probucol.
  • Examples of enhanced healing factors include, but are not limited to, BCP 671, VEGF, estradiols, NO donor comounds, and EPC antibodies.
  • radioactive compounds examples include, but are not limited to, strontium-89 chloride (Metastron®), samarium- 153 (Quadramet®), radium-223 di chloride (Xofigo®), yttrium-90, and iodine-131.
  • the drug-eluting compound and/or the drug-delivery features can carry more than one drug.
  • Figures 3A-3D are isometric views of portions of protruding members, such as drug-delivery features, carried by drug-eluting stents configured in accordance with additional embodiments of the present technology.
  • protruding members may be used with the drug-eluting stent 106 described above with reference to Figures 1 and 2, or other suitable drug-eluting and non drug-eluting stents configured in accordance with the present technology.
  • Figure 3 A illustrates a portion of a stent 300 including a frame 302 and a plurality of struts 304 having protruding members 306 (e.g., spikes, sharpened/tapered members, barbs, needles) configured to engage with and/or penetrate a portion of the body lumen, such as a vessel (not shown).
  • the protruding members 306 are integrally formed portions of the struts 304 and extend radially outward away from the stent 300 toward the target portion of the body lumen.
  • a drug-eluting stent 310 includes a strut 312 having drug-delivery features 314 carried thereon.
  • the drug-delivery features 314 are pointed conical protrusions.
  • the pointed conical protrusions can provide for penetration through a body lumen wall (e.g., a vessel wall) to deliver drugs directly into target tissue beyond the vessel wall. Vessels and target tissues are described above with reference to Figure 2A and 2B.
  • Figure 3C illustrates a portion of a drug-eluting stent 320 with a strut 322 carrying drug- delivery features 324.
  • the drug-delivery features 324 are pointed conical protrusions having ribbed surfaces and flattened tops.
  • the textured (e.g., ribbed) surfaces of the protruding and conical drug-delivery features 324 are expected to provide greater surface area for drug-delivery. While only illustrated on conical drug- delivery features 324, any drug-delivery features can include a textured surface such as a ribbed surface (vertical, horizontal, radial, or circular relative to a longitudinal plane of the drug-delivery feature), a cross-hatched surface, an isotropic surface, or other surface types suitable for providing greater surface area for drug-delivery.
  • Figure 3D illustrates a portion of a drug-eluting stent 330 including a strut 332 carrying drug-delivery features 334.
  • drug-delivery features 334 are wedge shaped protrusions configured to engage/penetrate through a vessel wall for drug-delivery.
  • the illustrated embodiments of Figures 2 and 3A-3D include protruding members, such as, drug-delivery features having a variety of shapes, it is to be understood that other embodiments can include drug-delivery features having alternative shapes to those shown in these Figures.
  • the drug-delivery features can be sized and shaped for placement within various body lumens, including vessels as described herein. The sizes and shapes can be selected to achieve a desired engagement with or penetration of certain features (e.g., target tissues) of the body lumen in which the drug-eluting stent 106 will be placed.
  • the drug-delivery features can have a number of shapes, including but not limited to, a cube, a square, a rectangular prism, a cylinder, a circle, a cone, a pyramid, curved-spikes, or other pointed shape. Any of these shapes can have flat, dull, pointed, and/or sharp distal portions.
  • the drug-delivery features can be sized and shaped to engage with and/or penetrate an occlusion, a neointima, an intima, an internal elastic lamina (IEL) a media, an external elastic lamina (EEL), an adventitia, or a combination thereof.
  • the drug-delivery features can also be sized and shaped to engage with and/or penetrate a tissue and/or structure adjacent to the body lumen in which the drug-eluting stent 106 is to be placed while not rupturing the body lumen.
  • the drug-eluting stent 106 can include square drug- delivery features sized and configured to penetrate into the intima and/or the media of a body lumen, pointed drug-delivery features sized and configured to penetrate and extend into the media, and/or the IEL.
  • drug-delivery features can be configured to bend in one or more directions relative to a longitudinal axis of the drug-eluting stent to engage with and/or penetrate a portion of the body lumen described herein.
  • the drug-delivery features can penetrate deeper into the wall of a diseased body lumen, such as a vessel, compared to a stent lacking drug-delivery features.
  • the drug-eluting stent can allow for blood to flow even while in the expanded position and with drug-eluting ongoing.
  • Various drug-delivery features described herein can deliver drugs deeper into a vessel wall than possible via angioplasty balloons or other existing devices.
  • the drug-delivery features can also carry a molecule suitable for degrading a portion of the occlusion, neointima, and/or intima to allow the drug-delivery features to penetrate deeper in to the vessel wall than without the molecule.
  • the molecule suitable for degradation can be an enzyme, such as elastase, collagenase, or a proteinase, such as, metalloproteinases, serine proteinases, cysteine
  • -l i - proteinases extracellular sulfatases, hyaluronidases, lysyl oxidases, lysyl hydroxylases, or a combination thereof.
  • drug-eluting stents configured in accordance with the present technology can carry one or more drug-delivery features on one or more portions of the stent.
  • the drug-eluting stents can carry about 5 drug- delivery features, about 10 drug-delivery features, about 15 drug-delivery features, about 20 drug-delivery features, about 30 drug-delivery features, about 40 drug-delivery features, about 50 drug-delivery features, about 60 drug-delivery features, about 70 drug-delivery features, about 80 drug-delivery features, about 90 drug-delivery features, or about 100 drug- delivery features.
  • the drug-delivery features can be carried by the frame 1 1 1, the struts 204, or a combination thereof.
  • the number of drug-delivery features can vary depending upon, for example, the target treatment site, the type of drug being delivered, and size of the stent, etc.
  • the drug-delivery features carried by the stent can be different types of the drug-delivery features disclosed herein.
  • FIG 4 is a cross-sectional view of a portion of a drug-eluting stent 400 including a strut 402 carrying drug-delivery feature 404 configured in accordance with yet another embodiment of the present technology.
  • the drug- delivery feature 404 includes a reservoir 406, and a drug 408 carried by the reservoir 406.
  • the reservoir 406 can at least partially contain the drug 408 and protect it from being prematurely released (e.g., via scraping during delivery of the associated stent through a catheter).
  • tissue and/or fluid can interact with the drug-delivery feature 404 to dissolve the drug 408 and selectively release it from the reservoir 406.
  • the drug-delivery feature can be configured to deliver the drug via a variety of means once the drug-eluting stent is expanded.
  • Drug-delivery feature 404 is accordingly expected to provide an effective means for selectively delivering a drug to a desired location, while reducing inadvertent loss or release of drugs.
  • the drug-eluting stent can include more than one drug- delivery feature, or a drug-delivery feature having more than one reservoir.
  • the stent including drug-delivery features configured in accordance with the present technology can have the drug-delivery feature, such as the coating or the reservoir, concealed (e.g., recessed) until the stent is positioned at the treatment site. Once positioned at the target site, the drug-delivery feature can be revealed (e.g., expanded/projected, etc.)
  • the drug-eluting stents can further include a material (e.g., PTFE, Dacron, polyamides, such as nylon and/or polyurethane based materials, silicone, etc.) positioned over a stent, scaffold or other structure having drug-delivery features covering at least a portion of the outer surface area.
  • the material covers the entire outer surface area.
  • the material can be a mesh or a braid.
  • the material can be configured to increase a surface area of the stent useful for providing additional surface area of the stent for coating with a drug.
  • the material can further be configured to allow blood flow through the inner diameter of the stent and/or limit blood flow to an outer dimension of the stent.
  • the material can create a barrier between fluid flow (e.g., blood flow) and the drug-delivery locations.
  • the material can be configured to prevent debris from the wall of the body lumen from entering the bloodstream.
  • the associated systems and devices can be used for temporary dissection tacking or coverage of a region that may have been perforated during a procedure.
  • the embodiments described herein provide a structure with a means for delivering drugs to a specific region within a body lumen, such as the vasculature, while still allowing fluid (e.g., blood) to flow through the treatment area where the structure has been placed and/or other devices or treatment means within the adjacent body lumen.
  • the drug-eluting stents are configured not to limit fluid flow (e.g., blood flow) through the body lumen (e.g., vessel).
  • the stent can be configured to prepare the body lumen for treatment, by raking the stent, pulling the stent, turning the stent, or a combination thereof, proximal or distal to the treatment site.
  • the drug- eluting stent can be configured to rotate when mechanical force is applied.
  • the systems disclosed herein can provide for adjustment, recapture, and redeployment of the associated stents or other structures, allowing a practitioner to more effectively to treat a desired region more accurately and deliberately.
  • the stent or other delivery structure can be deployed for a temporary period (e.g., for less than 24 hours), and then retracted and removed.
  • the drug-eluting stent can also be configured to post-dilate when removed from the body lumen.
  • the stent or other delivery structure can be deployed for a long-term temporary period (e.g., for less than 2 weeks, less than one month, less than 6 months, less than one year), and then retracted and removed.
  • a different stent or delivery structure can be deployed after a first stent or delivery structure has been retraced and removed.
  • the duration of deployment and duration after removal before deployment of the different stent or delivery structure can vary from minutes, to hours, to days, to weeks, to months, or to years.
  • removal of the first stent or delivery structure and deployment of a different stent or delivery structure can occur once, twice, three times, four times, five times, six times, seven times, eight times, nine times, or ten times.
  • the embodiments described herein can allow for a lower profile system than currently available balloons.
  • the stents and/or structures described herein include drug-eluting stents
  • additional embodiments of the expandable elements, such as stents and/or structures can include non drug-eluting stents and/or non drug-eluting structures.
  • the non drug-eluting stents may include one or more protruding members, such as spikes.
  • the spikes can be configured to engage with and/or penetrate a portion of the body lumen or vessel. For example, the spikes can penetrate the vessel wall, thereby reducing and/or eliminating an elasticity of the vessel wall.
  • the protruding members can be configured to prevent the vessel wall from progressing inward toward the lumen and restricting and/or constricting flow therein.
  • the protruding members can be integrally formed with the struts, or disposed on the surface of the struts, extending radially outward from the struts toward the target tissue.
  • a drug-eluting stent was placed within a vessel of a human patient post mortem.
  • Three different types of stents were used: (a) a metal stent having square drug-delivery features, (b) a metal stent having round drug-delivery features, and (c) a metal stent having sharpened/tapered drug-delivery features.
  • a stent having sharpened/tapered drug-delivery features was placed within a blood vessel of a human cadaver. Following placement of the sharpened/tapered drug-delivery feature stent, the vessel was removed from the cadaver, embedded in plastic, and sliced into cross-sections of a thickness suitable for histology. The cross-sections were stained using an Elastic Masson Trichrome stain, imaged, and evaluated for the positioning of the pointed drug-delivery feature stent in the vessel.
  • Figures 5A-5C include histology images taken after placement of the stent having the sharpened/tapered drug-delivery features within the vessel of the cadaver.
  • Figure 5A depicts a sharpened/tapered drug-delivery feature penetrated through the neointima, IEL, media, and engaging with the EEL.
  • Figure 5B depicts a sharpened/tapered drug-delivery feature penetrated through the neointima, IEL, and into the media.
  • Figure 5C depicts a sharpened/tapered drug-delivery feature penetrated through the neointima, IEL, media, and engaging with the EEL. None of the drug-delivery features described above in Example 1 perforated the vessel.
  • a stent having square or rectilinear drug-delivery features was placed within a blood vessel of a human cadaver. Following placement of the square drug- delivery feature stent, the vessel was removed from the cadaver, embedded in plastic, and sliced into cross-sections of a thickness suitable for histology. The cross-sections were stained using an Elastic Masson Trichrome stain, imaged, and evaluated for the positioning of the square drug-delivery feature stent in the vessel.
  • Figures 6A-60 include histology images taken after placement of the stent having the square drug-delivery features in a vessel of the cadaver.
  • Figure 6A depicts a square drug-delivery feature having a width of 96.79 ⁇ and a depth of 1 15.62 ⁇ .
  • Figures 6B and 6C depict two square drug-delivery features with one engaging with the neointima and one pushing the neointima into the IEL.
  • Figure 6D depicts one square drug- delivery feature with one engaging with the neointima and one engaging with the media.
  • Figure 6E depicts one square drug-delivery feature with one engaging with the neointima.
  • Figure 6F depicts three square drug-delivery features with one engaging with the neointima.
  • Figures 6G and 6H depict square drug-delivery features pushing the neointima into the IEL.
  • Figure 61 depicts one square drug-delivery feature engaging with the IEL.
  • Figure 6J depicts square drug-delivery features penetrating the neointima and others pushing the neointima into the IEL.
  • Figure 6K depicts a square drug-delivery feature engaging with the neointima.
  • Figure 6L depicts square drug-delivery features penetrating the neointima.
  • Figure 6M depicts square drug-delivery features engaging the neointima and others penetrating into the intima engaging with the IEL.
  • Figure 6N depicts square drug-delivery features engaging the neointima.
  • Figure 60 depicts square drug-delivery features engaging the neointima and others penetrating into the media. None of the drug-delivery features associated with Example 2 perforated the vessel.
  • a stent having round or rounded drug-delivery features was placed within a blood vessel of a human cadaver. Following placement of the round drug- delivery feature stent, the vessel was removed from the cadaver, embedded in plastic, and sliced into cross-sections of a thickness suitable for histology. The cross-sections were stained using an Elastic Masson Trichrome stain, imaged, and evaluated for the positioning of the round drug-delivery feature stent in the vessel.
  • Figures 7A-7C include histology images taken after placement of the stent having round drug-delivery features in a vessel of the human patient.
  • Figure 7A depicts a round drug-delivery feature having a diameter of 651.41 ⁇ .
  • Figure 7B depicts a round drug- delivery feature engaging with the neointima and pushing the neointima into the IEL.
  • Figure 7C depicts a round drug-delivery feature engaging with the neointima and others penetrating into the media. None of the drug-delivery features associated with Example 3 perforated the vessel.
  • a stent having sharpened/tapered drug-delivery features was placed within a blood vessel of a human cadaver. Following placement of the sharpened/tapered drug-delivery feature stent, the vessel was removed from the patient, embedded in plastic, and sliced into cross-sections of a thickness suitable for histology. The cross-sections were stained using an Elastic Masson Trichrome stain, imaged, and evaluated for the positioning of the sharpened/tapered drug-delivery feature stent in the vessel.
  • Figures 8A-8H include histology images taken after placement of the stent having the sharpened/tapered drug-delivery features in a vessel of the cadaver.
  • Figure 8A depicts a sharpened/tapered drug-delivery feature having a maximum width of 193.32 ⁇ and a length of 868.88 ⁇ .
  • Figure 8B depicts a sharpened/tapered drug-delivery feature penetrating through the neointima, through the IEL, and engaging with the media.
  • Figures 8C and 8D depict a sharpened/tapered drug-delivery feature penetrating through the neointima, through the IEL, through the media, and engaging the EEL.
  • Figure 8E depicts a sharpened/tapered drug-delivery feature penetrating through the neointima, through the IEL, and engaging the media.
  • Figure 8F depicts a sharpened/tapered drug-delivery feature engaging the neointima.
  • Figure 8G depicts a sharpened/tapered drug-delivery feature penetrating through the neointima, through the IEL, through the media, and engaging the EEL.
  • Figure 8H depicts a sharpened/tapered drug-delivery feature penetrating through the neointima, through the IEL, and penetrating the media. None of the sharpened/tapered drug- delivery features described herein with respect to Example 4 perforated the vessel.
  • E. EXAMPLE 5 Stents Having Square Drug-delivery Features Placed Near an Atheroma. Atherosclerotic Lesion, and/or Calcification
  • a stent having square or rectilinear drug-delivery features was placed within a blood vessel of a human cadaver. Following placement of the square drug- delivery feature stent, the vessel was removed from the patient, embedded in plastic, and sliced into cross-sections of a thickness suitable for histology. The cross-sections were stained using an H&E stain, imaged, and evaluated for the positioning of the square drug- delivery feature stent in the vessel.
  • Figures 9A-9K include histology images taken after placement of the stent having the square drug-delivery features in a vessel of the cadaver.
  • Figure 9A depicts a square drug-delivery feature having a width of 248.47 ⁇ and a depth of 292.40 ⁇ .
  • Figure 9B depicts 22 square drug-delivery features either engaging with the neointima, pushing the neointima into the IEL, or engaging with a plaque having calcifications.
  • Figure 9C depicts square drug-delivery features engaging with the neointima, engaging with a plaque having calcifications, or engaging with the non-calcified intima.
  • Figure 9D depicts square drug-delivery features engaging with the IEL and others penetrating the intima and media having calcifications.
  • Figure 9E depicts square drug-delivery features engaging with the IEL and others pushing the neointima into the IEL.
  • Figure 9F depicts square drug- delivery features penetrating the neointima and others penetrating the media.
  • Figure 9G depicts square drug-delivery features engaging with a calcified atheroma, others penetrating the neointima, and another penetrating the media.
  • Figure 9H is a higher magnification of a portion of the atheroma depicted in Figure 9G.
  • Figure 91 depicts square drug-delivery features engaging the neointima and the media of a calcified atherosclerotic plaque.
  • Figure 9J is a higher magnification of a portion of the atheroma depicted in Figure 91.
  • Figure 9K is a higher magnification of a portion of the atheroma depicted in Figure 9J. None of the drug-delivery features associated with Example 5 perforated the vessel.
  • An expandable element for treating a human patient comprising:
  • a radially expandable cylindrical frame or braided mesh having a plurality of struts or wires, wherein the frame is transformable between a low-profile delivery state and an expanded deployed state;
  • a plurality of drug-delivery features carried by one or more struts and configured to deliver a drug to a treatment site within a body lumen of the patient, wherein, when the frame is in the expanded state within the body lumen—
  • the drug-delivery features extend radially outwardly away from the strut, and the drug-delivery features are configured to engage the first portion of the body lumen.
  • the plurality of drug-delivery features comprise a first set of drug-delivery features, a second set of drug- delivery features, and a third set of drug-delivery features, and wherein the first, second, and third sets are carried by a first strut, a second different strut, and a third different strut, respectively.
  • the plurality of drug-delivery features comprise a first set of drug-delivery features configured to deliver a first drug to the patient and a second set of drug-delivery features configured to deliver a second drug to the patient, and wherein the first drug and the second drug are different.
  • the plurality of drug-delivery features comprise reservoirs integrally formed therein.
  • a method for treating a human patient with an expandable element comprising:
  • the expandable element comprises— a radially expandable cylindrical frame having a plurality of struts; and a plurality of drug-delivery features carried by one or more struts and configured to deliver a drug to a treatment site within a body lumen of the patient; and
  • the drug- delivery features extend radially outwardly away from the strut and pierce through a wall of the body lumen to engage with a first portion of the body lumen and, optionally, extend into a second portion of the body lumen to deliver the drug thereto.
  • the plurality of drug- delivery features comprise a first set of drug-delivery features configured to deliver a first drug to the patient and a second set of drug-delivery features configured to deliver a second drug to the patient, and wherein the first drug and the second drug are the same drug or different drugs.

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

L'invention concerne des éléments extensibles, pourvus d'éléments d'administration de médicament, et des systèmes et des procédés associés. Dans un mode de réalisation, un stent à élution de médicament comprend un cadre cylindrique radialement extensible pourvu d'une pluralité d'entretoises. Le cadre est transformable entre un état d'administration à profil bas et un état déployé étendu. Une pluralité d'éléments d'administration de médicament sont soutenus par l'une des entretoises et conçus pour administrer un médicament sur un site de traitement dans le corps du patient ou percer la paroi tissulaire afin d'interrompre la constriction de la paroi du vaisseau vers l'intérieur. Lorsque le cadre est à l'état déployé dans une lumière corporelle du patient, les éléments d'administration de médicament s'étendent radialement vers l'extérieur à l'écart de l'entretoise et sont conçus pour venir en contact et, dans certains agencements, traverser une paroi de la lumière corporelle.
PCT/US2016/056688 2015-10-12 2016-10-12 Stents pourvus d'éléments saillants d'administration de médicament et systèmes et procédés associés WO2017066355A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA3001249A CA3001249C (fr) 2015-10-12 2016-10-12 Stents pourvus d'elements saillants d'administration de medicament et systemes et procedes associes
EP16856132.2A EP3362006B1 (fr) 2015-10-12 2016-10-12 Stents pourvus d'éléments saillants d'administration de médicament et systèmes
AU2016339033A AU2016339033B2 (en) 2015-10-12 2016-10-12 Stents having protruding drug-delivery features and associated systems and methods
CN202211482262.7A CN115778654A (zh) 2015-10-12 2016-10-12 具有突出的药物递送特征部的支架以及相关的系统和方法
JP2018538539A JP7145757B2 (ja) 2015-10-12 2016-10-12 突出する薬剤送達フィーチャーを有するステント、ならびに、関連のシステムおよび方法
CN201680072455.1A CN108366866A (zh) 2015-10-12 2016-10-12 具有突出的药物递送特征部的支架以及相关的系统和方法
ES16856132T ES2906444T3 (es) 2015-10-12 2016-10-12 Endoprótesis (stents) con características de suministro de medicamentos y sistemas asociados.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562240320P 2015-10-12 2015-10-12
US62/240,320 2015-10-12

Publications (1)

Publication Number Publication Date
WO2017066355A1 true WO2017066355A1 (fr) 2017-04-20

Family

ID=58499124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/056688 WO2017066355A1 (fr) 2015-10-12 2016-10-12 Stents pourvus d'éléments saillants d'administration de médicament et systèmes et procédés associés

Country Status (8)

Country Link
US (3) US10172729B2 (fr)
EP (1) EP3362006B1 (fr)
JP (2) JP7145757B2 (fr)
CN (2) CN108366866A (fr)
AU (1) AU2016339033B2 (fr)
CA (1) CA3001249C (fr)
ES (1) ES2906444T3 (fr)
WO (1) WO2017066355A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5526038B2 (ja) * 2008-01-17 2014-06-18 ボストン サイエンティフィック サイムド，インコーポレイテッド 移動防止特徴部を備えたステント
US8323243B2 (en) 2008-03-21 2012-12-04 Innovasc Llc Device and method for opening blood vessels by pre-angioplasty serration and dilatation of atherosclerotic plaque
US11229777B2 (en) 2008-03-21 2022-01-25 Cagent Vascular, Inc. System and method for plaque serration
US9480826B2 (en) 2008-03-21 2016-11-01 Cagent Vascular, Llc Intravascular device
US10463842B2 (en) 2014-06-04 2019-11-05 Cagent Vascular, Llc Cage for medical balloon
AU2015343272B2 (en) 2014-11-03 2020-07-16 Cagent Vascular, Inc. Serration balloon
AU2016324292B2 (en) 2015-09-17 2021-06-10 Cagent Vascular, Inc. Wedge dissectors for a medical balloon
AU2017361422B2 (en) 2016-11-16 2023-07-06 Cagent Vascular, Inc. Systems and methods of depositing drug into tissue through serrations
CA3073831C (fr) 2017-09-12 2022-07-26 W. L. Gore & Associates, Inc. Substrat dote d'entretoises rotatives pour dispositif medical
US11318288B2 (en) 2018-03-27 2022-05-03 Gyrus Acmi, Inc. Instrument for delivering substances into the anatomy
AU2019310102B2 (en) 2018-07-25 2025-03-06 Cagent Vascular, Inc. Medical balloon catheters with enhanced pushability
CN112888406B (zh) * 2018-10-08 2025-03-18 瑞弗罗医疗公司 用于具有突出特征的支架的输送系统
DE102019116791B4 (de) 2019-06-21 2023-10-26 InnoRa Gesellschaft mbH Stent mit sofort ablösbarer Beschichtung
US11565079B2 (en) 2019-08-13 2023-01-31 Reflow Medical, Inc. Support catheter
WO2021087362A1 (fr) 2019-11-01 2021-05-06 Reflow Medical, Inc. Dispositifs de récupération ayant des éléments en saillie pour thrombectomie
JP2022553794A (ja) * 2019-11-04 2022-12-26 リフロー メディカル インコーポレイテッド 固着のための突出フィーチャを有するステント
CN115038412A (zh) 2019-12-24 2022-09-09 包围血管公司 用于流体递送的医疗装置
WO2021258062A1 (fr) * 2020-06-19 2021-12-23 Massachusetts Institute Of Technology Stents endovasculaires injectables pour l'administration cardiovasculaire de médicament
US20210393422A1 (en) * 2020-06-19 2021-12-23 Massachusetts Institute Of Technology Kirigami-inspired stents for sustained local delivery of therapeutics
WO2022031730A1 (fr) 2020-08-03 2022-02-10 Patsalides Athos Endoprothèse intracrânienne destinée à être insérée dans le système de sinus veineux cérébral et procédés d'utilisation
WO2022182598A1 (fr) 2021-02-23 2022-09-01 Encompass Vascular, Inc. Dispositifs médicaux pour la distribution de fluide et procédés d'utilisation et de fabrication
EP4329855A4 (fr) 2021-04-30 2025-03-26 Encompass Vascular Inc Dispositifs médicaux pour la distribution de fluide et procédés d'utilisation et de fabrication
US12005227B2 (en) 2021-10-06 2024-06-11 Product Realization Specialites, LLC Direct drug/therapeutic infusion via trans-vascular glymphatic system and method
WO2024191445A1 (fr) * 2023-03-10 2024-09-19 Becton, Dickinson And Company Échafaudage polymère bio-absorbable thérapeutique avec micro-aiguilles chargées de médicament pour l'administration de médicament

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003948A1 (fr) * 2001-07-06 2003-01-16 Tricardia, L.L.C. Dispositifs anti-arythmie et leurs utilisations
WO2004043509A1 (fr) 2002-11-08 2004-05-27 Conor Medsystems, Inc. Dispositif medical extensible et procede de traitement d'occlusions totales chroniques par administration locale d'un facteur angiogenique
US20040161446A1 (en) * 1999-12-30 2004-08-19 Bhat Vinayak D. Process for agent retention in biological tissues
US20060287709A1 (en) * 2002-11-13 2006-12-21 Advanced Cardiovascular Systems, Inc. Drug-eluting stent and methods of making the same
US20070213761A1 (en) * 2006-02-24 2007-09-13 National University Of Ireland, Galway Minimally invasive intravascular treatment device
US8109904B1 (en) * 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824041A (en) 1994-06-08 1998-10-20 Medtronic, Inc. Apparatus and methods for placement and repositioning of intraluminal prostheses
CA2171896C (fr) 1995-03-17 2007-05-15 Scott C. Anderson Extenseur a ancrage multiple
US6197013B1 (en) 1996-11-06 2001-03-06 Setagon, Inc. Method and apparatus for drug and gene delivery
AU6296398A (en) * 1997-02-07 1998-08-26 Leuven Research & Development Vzw Gene therapeutic treatment of blood vessel associated disorders
US6048360A (en) 1997-03-18 2000-04-11 Endotex Interventional Systems, Inc. Methods of making and using coiled sheet graft for single and bifurcated lumens
US6425915B1 (en) 1997-03-18 2002-07-30 Endotex Interventional Systems, Inc. Helical mesh endoprosthesis and methods of use
US6290728B1 (en) 1998-09-10 2001-09-18 Percardia, Inc. Designs for left ventricular conduit
EP1112043B1 (fr) 1998-09-10 2006-04-05 Percardia, Inc. Shunt de revascularisation transmyocardique
US6991643B2 (en) * 2000-12-20 2006-01-31 Usgi Medical Inc. Multi-barbed device for retaining tissue in apposition and methods of use
US6800089B1 (en) 2000-05-31 2004-10-05 Advanced Cardiovascular Systems, Inc. Mechanical attachment method of cover materials on stents
US7651696B2 (en) 2000-08-25 2010-01-26 Nexeon Medical Systems, Inc. Implantable device for treating disease states and methods of using same
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US6805898B1 (en) 2000-09-28 2004-10-19 Advanced Cardiovascular Systems, Inc. Surface features of an implantable medical device
AU780393B2 (en) * 2000-11-16 2005-03-17 Cordis Corporation An improved stent for use in a stent graft
WO2002055136A2 (fr) 2000-12-01 2002-07-18 Nephros Therapeutics Inc Dispositif d'administration de medicaments intravasculaire et son utilisation
AU2002249826A1 (en) * 2000-12-22 2002-07-30 Avantec Vascular Corporation Delivery of therapeutic capable agents
BR0209046A (pt) * 2001-04-20 2004-11-09 Alza Corp Disposição de microprojeção que possui um agente benéfico contendo revestimento
US6808518B2 (en) * 2001-09-28 2004-10-26 Ethicon, Inc. Methods and devices for treating diseased blood vessels
US7892273B2 (en) 2001-12-03 2011-02-22 Xtent, Inc. Custom length stent apparatus
AUPR969201A0 (en) 2001-12-20 2002-01-24 White, Geoffrey H. A device for use in intraluminal grafting
WO2003063729A2 (fr) 2002-01-28 2003-08-07 Orbus Medical Technologies Inc. Endoprothese ostiale evasee et systeme d'apport
US7044962B2 (en) 2002-06-25 2006-05-16 Scimed Life Systems, Inc. Implantable prosthesis with displaceable skirt
AU2003256499A1 (en) 2002-07-11 2004-02-02 Setagon, Inc. Expandable body having deployable microstructures and related methods
AU2003249017A1 (en) 2002-07-11 2004-02-02 Setagon, Inc. Methods and apparatuses for repairing aneurysms
US20050096731A1 (en) 2002-07-11 2005-05-05 Kareen Looi Cell seeded expandable body
US20040034407A1 (en) 2002-08-16 2004-02-19 John Sherry Covered stents with degradable barbs
US6991617B2 (en) * 2002-08-21 2006-01-31 Hektner Thomas R Vascular treatment method and device
US7001422B2 (en) 2002-09-23 2006-02-21 Cordis Neurovascular, Inc Expandable stent and delivery system
FR2845590B1 (fr) * 2002-10-10 2005-10-21 Jean Francois Garbe Dispositif de liaison entre une prothese et un conduit corporel et dispositif de connexion de deux conduits corporels disposes bout a bout
AU2003284088A1 (en) 2002-10-11 2004-05-04 Boston Scientific Limited Implantable medical devices
US20040098116A1 (en) 2002-11-15 2004-05-20 Callas Peter L. Valve annulus constriction apparatus and method
BR0316956A (pt) * 2002-12-02 2005-10-25 Gi Dynamics Inc Dispositivo de implante gastrointestinal; método de tratamento; método de tratamento de diabetes do tipo 2; sistema de entrega para colocar um dispositivo de implante gastrointestinal em um corpo; dispositivo de remoção para remover um dispositivo de implante gastrointestinal do corpo; e aparelho de entrega
US20050165469A1 (en) 2002-12-24 2005-07-28 Michael Hogendijk Vascular prosthesis including torsional stabilizer and methods of use
US7846198B2 (en) 2002-12-24 2010-12-07 Novostent Corporation Vascular prosthesis and methods of use
US7753945B2 (en) 2003-01-17 2010-07-13 Gore Enterprise Holdings, Inc. Deployment system for an endoluminal device
EP1611920B1 (fr) 2003-03-10 2009-05-13 Kaneka Corporation Stent
ATE381913T1 (de) 2003-04-02 2008-01-15 Boston Scient Ltd Abnehmbare und rückholbare stentanordnung
US7122043B2 (en) 2003-05-19 2006-10-17 Stout Medical Group, L.P. Tissue distention device and related methods for therapeutic intervention
US20030216803A1 (en) 2003-05-28 2003-11-20 Ledergerber Walter J. Textured and drug eluting stent-grafts
US7041127B2 (en) 2003-05-28 2006-05-09 Ledergerber Walter J Textured and drug eluting coronary artery stent
EP1635734A2 (fr) 2003-06-09 2006-03-22 MacroPore Biosurgery, Inc. Stent endoluminal helicoidal et procedes connexes
US20050049692A1 (en) 2003-09-02 2005-03-03 Numamoto Michael J. Medical device for reduction of pressure effects of cardiac tricuspid valve regurgitation
US8876882B2 (en) * 2003-10-10 2014-11-04 Mark Gelido Barongan Cutting stent
US7258697B1 (en) 2003-12-22 2007-08-21 Advanced Cardiovascular Systems, Inc. Stent with anchors to prevent vulnerable plaque rupture during deployment
US8092549B2 (en) * 2004-09-24 2012-01-10 The Invention Science Fund I, Llc Ciliated stent-like-system
US7470252B2 (en) * 2004-09-16 2008-12-30 Boston Scientific Scimed, Inc. Expandable multi-port therapeutic delivery system
US9788978B2 (en) 2004-12-20 2017-10-17 Nicholas A. Rojo Implantable systems and stents containing cells for therapeutic uses
FR2880796B1 (fr) 2005-01-18 2008-02-22 Novatech Sa Sa Endoprothese pour canal anotomique
US7320702B2 (en) 2005-06-08 2008-01-22 Xtent, Inc. Apparatus and methods for deployment of multiple custom-length prostheses (III)
DE102006017873A1 (de) 2005-07-14 2007-01-25 Qualimed Innovative Medizinprodukte Gmbh Temporärer Stent
WO2007016166A2 (fr) * 2005-07-27 2007-02-08 Cook Critical Care Incorporated Endoprothese couverte et procede d'implantation chirurgicale ouverte
US8771340B2 (en) 2005-08-25 2014-07-08 Cook Medical Technologies Llc Methods and devices for the endoluminal deployment and securement of prostheses
US20070191811A1 (en) 2006-02-10 2007-08-16 Joseph Berglund System and Method for Treating a Vascular Condition
GB2440332A (en) * 2006-07-22 2008-01-30 George Andrew Francis Roberts Polymer-metal complexes
JP5156749B2 (ja) * 2006-09-15 2013-03-06 カーディアック ペースメイカーズ， インコーポレイテッド 植え込み型センサ用アンカー
US20110257723A1 (en) * 2006-11-07 2011-10-20 Dc Devices, Inc. Devices and methods for coronary sinus pressure relief
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
EP2107895A1 (fr) 2007-01-29 2009-10-14 Cook Incorporated Prothèse médicale et procédé de production
JP5461202B2 (ja) * 2007-03-09 2014-04-02 アイコン メディカル コーポレーション 医療用具用生体吸収性コーティング
WO2008125145A1 (fr) * 2007-04-13 2008-10-23 Synergio Ag Dispositif et procédé de pénétration tissulaire
US8778012B2 (en) 2012-11-27 2014-07-15 Cormatrix Cardiovascular, Inc. ECM constructs for tissue regeneration
US9149496B2 (en) 2007-05-10 2015-10-06 Cormatrix Cardiovascular, Inc. ECM Constructs for treating damaged biological tissue
US8007470B2 (en) 2007-07-10 2011-08-30 Cook Medical Technologies Llc Minimally invasive medical device and method for delivery of therapeutic or diagnostic agents into a vessel wall
US9566178B2 (en) * 2010-06-24 2017-02-14 Edwards Lifesciences Cardiaq Llc Actively controllable stent, stent graft, heart valve and method of controlling same
US20090062839A1 (en) * 2007-08-31 2009-03-05 Cook Incorporated Barbed stent vascular occlusion device
US9198687B2 (en) * 2007-10-17 2015-12-01 Covidien Lp Acute stroke revascularization/recanalization systems processes and products thereby
JP5693228B2 (ja) * 2007-11-14 2015-04-01 バイオセンサーズ インターナショナル グループ、リミテッド 自動被覆装置および方法
US8128677B2 (en) 2007-12-12 2012-03-06 Intact Vascular LLC Device and method for tacking plaque to a blood vessel wall
US8187316B2 (en) 2007-12-27 2012-05-29 Cook Medical Technologies Llc Implantable graft device having treated yarn and method for making same
US20100042206A1 (en) * 2008-03-04 2010-02-18 Icon Medical Corp. Bioabsorbable coatings for medical devices
US8323243B2 (en) * 2008-03-21 2012-12-04 Innovasc Llc Device and method for opening blood vessels by pre-angioplasty serration and dilatation of atherosclerotic plaque
US9480826B2 (en) * 2008-03-21 2016-11-01 Cagent Vascular, Llc Intravascular device
US9138233B2 (en) * 2011-03-17 2015-09-22 Micokoll Inc. Apparatus and method for tissue adhesion
GB2469072A (en) 2009-03-31 2010-10-06 Royal Brompton & Harefield Nhs Guidewire with Anchor for a catheter
GB2469297B (en) 2009-04-07 2011-05-25 Cook Inc Introducer assembly and implantable medical device
US8764712B2 (en) * 2009-08-04 2014-07-01 Cook Medical Technologies Llc Micro-needle array and method of use thereof
US9757107B2 (en) * 2009-09-04 2017-09-12 Corvia Medical, Inc. Methods and devices for intra-atrial shunts having adjustable sizes
EP2481378A4 (fr) 2009-09-25 2014-01-08 Kyoto Medical Planning Co Ltd Dispositif de cathéter médical
JP5918700B2 (ja) * 2010-01-29 2016-05-18 アイコン メディカル コーポレーション 膨張可能な器具上の生分解性突起
NZ602849A (en) 2010-03-25 2014-05-30 Lutonix Inc Drug releasing coatings for medical devices
EP2545887B1 (fr) 2010-03-30 2016-08-10 Terumo Kabushiki Kaisha Système de pose d'endoprothèse
US20110295353A1 (en) 2010-04-29 2011-12-01 Vanderbilt University Patent body lumen stent
DE102010022588A1 (de) 2010-05-27 2011-12-01 Hemoteq Ag Ballonkatheter mit einer partikelfrei Wirkstoff-abgebenden Beschichtung
US8337542B2 (en) 2010-07-14 2012-12-25 Cook Medical Technologies Llc Delivery system for simultaneous deployment of intraluminal device
US20120095542A1 (en) 2010-10-15 2012-04-19 Cook Incorporated Intraluminal medical device
EP2450010B1 (fr) 2010-11-09 2013-11-20 Biotronik AG Cathéter à ballonnet, notamment destiné à l'administration de médicaments ou de stents dans la zone d'une sténose
WO2012071224A1 (fr) * 2010-11-24 2012-05-31 Cook Medical Technologies Llc Filtre vasculaire en forme de dôme
DE102011011869A1 (de) * 2011-02-22 2012-08-23 Phenox Gmbh Implantat
US10092426B2 (en) * 2011-05-31 2018-10-09 Cook Medical Technologies Llc Non-foreshortening, axial tension constrainable stent
US8715334B2 (en) 2011-07-14 2014-05-06 Boston Scientific Scimed, Inc. Anti-migration stent with quill filaments
CN103889474B (zh) 2011-08-15 2016-09-07 Meko激光材料加工公司 镁合金和包含该镁合金的可吸收的支架
US9675473B2 (en) 2011-12-29 2017-06-13 Boston Scientific Scimed, Inc. Stent with anti-migration features
US9011513B2 (en) 2012-05-09 2015-04-21 Abbott Cardiovascular Systems Inc. Catheter having hydraulic actuator
US9848976B2 (en) 2012-06-05 2017-12-26 Kardiozis Endoprosthesis, delivery device and a method for implanting such endoprosthesis
WO2014044789A1 (fr) 2012-09-21 2014-03-27 Materialise N.V. Implants intraluminaux spécifiques au patient
EP2911711A4 (fr) 2012-10-26 2016-05-25 Urotronic Inc Cathéters à ballon enduits de médicament pour strictions non vasculaires
US9585741B2 (en) * 2013-02-22 2017-03-07 NeuroVasc Technologies, Inc Embolus removal device with blood flow restriction and related methods
US9855160B2 (en) 2013-03-14 2018-01-02 W. L. Gore & Associates, Inc. Endoprosthesis delivery systems with deployment aids
ES2632451T3 (es) 2013-03-15 2017-09-13 Boston Scientific Scimed, Inc. Revestimiento de stent con micromotivos antimigración
CN110251283A (zh) 2013-03-15 2019-09-20 波士顿科学国际有限公司 抗迁移支架涂层
US10285702B2 (en) 2013-04-24 2019-05-14 Trustees Of Tufts College Bioresorbable biopolymer anastomosis devices
US10076399B2 (en) * 2013-09-13 2018-09-18 Covidien Lp Endovascular device engagement
GB2527761A (en) * 2014-06-30 2016-01-06 Cook Medical Technologies Llc Improved vascular filter and anchoring arrangement therefor
US10617435B2 (en) * 2014-11-26 2020-04-14 Neuravi Limited Clot retrieval device for removing clot from a blood vessel
US9375336B1 (en) 2015-01-29 2016-06-28 Intact Vascular, Inc. Delivery device and method of delivery
US10307273B2 (en) 2015-03-03 2019-06-04 Boston Scientific Scimed, Inc. Stent with anti-migration features
US10765539B2 (en) * 2015-05-27 2020-09-08 W. L. Gore & Associates, Inc. Stent graft device with anchoring members having adjustable geometries
EP3352689B1 (fr) * 2015-09-21 2018-12-26 Stryker Corporation Dispositifs d'embolectomie
US9808359B2 (en) * 2015-09-30 2017-11-07 Neurvana Medical, Llc Treatment systems processes and devices addressing cerebral vasospasm/vasoconstriction
US10893869B2 (en) * 2016-03-24 2021-01-19 Covidien Lp Thin wall constructions for vascular flow diversion
EP3342433A1 (fr) 2016-12-27 2018-07-04 MeKo Laserstrahl-Materialbearbeitungen e.K. Endoprothèse en alliage de magnésium biodégradable ayant un revêtement de fluorure de magnésium et un revêtement organique
US20180303594A1 (en) 2017-04-21 2018-10-25 Merit Medical Systems, Inc. Deployable stents and related devices, systems, and methods
US10575972B2 (en) * 2017-04-28 2020-03-03 Cook Medical Technologies Llc Medical device with induction triggered anchors and system for deployment of the same
US20210154372A1 (en) 2017-05-15 2021-05-27 C.R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
US10888410B2 (en) 2017-06-16 2021-01-12 Boston Scientific Scimed, Inc. Stent and sleeve deployment
US20200171214A1 (en) 2017-07-07 2020-06-04 Drei Lilien Pvg Gmbh & Co. Kg Bioresorbable surface coating for delaying degradation
CA3073831C (fr) * 2017-09-12 2022-07-26 W. L. Gore & Associates, Inc. Substrat dote d'entretoises rotatives pour dispositif medical
EP3494936A1 (fr) 2017-12-05 2019-06-12 Cook Medical Technologies LLC Ensemble de dispositif d'administration d'endogreffe
KR102596922B1 (ko) * 2018-06-04 2023-11-01 보스톤 싸이엔티픽 싸이메드 인코포레이티드 제거 가능한 스텐트
US10842498B2 (en) * 2018-09-13 2020-11-24 Neuravi Limited Systems and methods of restoring perfusion to a vessel
US11541152B2 (en) 2018-11-14 2023-01-03 Lutonix, Inc. Medical device with drug-eluting coating on modified device surface
JP2022521000A (ja) 2019-02-22 2022-04-04 ウロトロニック・インコーポレイテッド 体腔用薬物コーティングバルーンカテーテル
JP6989580B2 (ja) * 2019-11-15 2022-01-05 株式会社Biomedical Solutions ステント及びその検査方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161446A1 (en) * 1999-12-30 2004-08-19 Bhat Vinayak D. Process for agent retention in biological tissues
WO2003003948A1 (fr) * 2001-07-06 2003-01-16 Tricardia, L.L.C. Dispositifs anti-arythmie et leurs utilisations
WO2004043509A1 (fr) 2002-11-08 2004-05-27 Conor Medsystems, Inc. Dispositif medical extensible et procede de traitement d'occlusions totales chroniques par administration locale d'un facteur angiogenique
US20060287709A1 (en) * 2002-11-13 2006-12-21 Advanced Cardiovascular Systems, Inc. Drug-eluting stent and methods of making the same
US20070213761A1 (en) * 2006-02-24 2007-09-13 National University Of Ireland, Galway Minimally invasive intravascular treatment device
US8109904B1 (en) * 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices

Also Published As

Publication number Publication date
CN115778654A (zh) 2023-03-14
US20170100266A1 (en) 2017-04-13
JP7145757B2 (ja) 2022-10-03
AU2016339033B2 (en) 2021-04-08
JP2018531135A (ja) 2018-10-25
CN108366866A (zh) 2018-08-03
US10172729B2 (en) 2019-01-08
ES2906444T3 (es) 2022-04-18
US20190201219A1 (en) 2019-07-04
EP3362006B1 (fr) 2021-11-24
AU2016339033A1 (en) 2018-04-26
US11253379B2 (en) 2022-02-22
EP3362006A1 (fr) 2018-08-22
CA3001249C (fr) 2023-10-17
US20170196717A1 (en) 2017-07-13
EP3362006A4 (fr) 2019-05-15
US10258487B2 (en) 2019-04-16
JP2021168946A (ja) 2021-10-28
CA3001249A1 (fr) 2017-04-20

Similar Documents

Publication Publication Date Title
AU2016339033B2 (en) Stents having protruding drug-delivery features and associated systems and methods
JP2018531135A6 (ja) 突出する薬剤送達フィーチャーを有するステント、ならびに、関連のシステムおよび方法
US20040236414A1 (en) Devices and methods for treatment of stenotic regions
US11648139B2 (en) Delivery systems for stents having protruding features
JPWO2003004089A1 (ja) ステント
EP1871439A2 (fr) Endoprothese biodegradable/non biodegradable hybride, systeme de mise en place et methode de traitement d'une affection vasculaire
JP4876916B2 (ja) ステント
WO2019086684A1 (fr) Endoprothèse expansible et méthode pour favoriser un processus d'angiogenèse intracrânienne naturelle, et utilisation de l'endoprothèse expansible dans ladite méthode
JP2024153684A (ja) 突出フィーチャを有するステントのための送達システム
JP2003093520A (ja) ステント
JP2007105268A (ja) ステント

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16856132

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3001249

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2018538539

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016339033

Country of ref document: AU

Date of ref document: 20161012

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016856132

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载